 |
|
|
| |
Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of
Fibrosing Cholestatic Hepatitis C After Liver Transplantation
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Xavier Forns,1 David Mutimer,2 Michael Manns,3 K. Rajender Reddy,4 Gregory T. Everson,5 Steven L. Flamm,6 Jill Denning,7 Sarah Arterburn,7
Theo Brandt-Sarif,7 Phillip S. Pang,7 John G. McHutchison,7 Nezam Afdhal,8 Michael Charlton,9 Didier Samuel,10 Edward Gane11
1Liver Unit, IDIBAPS, CIBEREHD Hospital Clinic, Barcelona, Spain; 2Queen Elizabeth Hospital and University of Birmingham, Birmingham, UK; 3Hannover Medical School, Hannover, Germany; 4University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; 5University of Colorado Denver, Aurora, Colorado, USA; 6Northwestern Feinberg School of Medicine, Chicago, Illinois, USA; 7Gilead Sciences, Inc., Foster City, California, USA; 8Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; 9Intermountain Medical Center, Murray, Utah, USA; 10Université Paris-Sud, Villejuif, France; 11University of Auckland, Auckland, New Zealand
*Possibly secondary to either steatosis from poorly controlled insulin-dependent diabetes and/or amoxicillin/clavulanate-induced
cholestasis. Biliary stricture requiring stenting. Missing values [bilirubin]:
Week 6 (n=1), FU-12 (3); [GGT]: Scr (1), BL (1), Week 6 (1),
FU-12 (3); [ALT]: Week 2 (1), Week 6 (2), FU-12 (3). BL, baseline; Scr, screening; FU-12, follow-up Week 12.
|
| |
|
|
|
|
|
